



BÖLÜM 32

Rektum Kanseri ve Cerrahisi

Op. Dr. Sami BENLİ¹

Giriş

Rektum kanseri insidansı Avrupa Birliği ülkelerinde yılda yaklaşık 125000 vaka iken rektum kanserleri toplam kolorektal kanserlerin %35'ini oluşturmaktadır ve yıllık vaka sayısı 15-25/100000'dir (1). Türkiye'de ise kolorektal kanserler her iki cinsiyette de üçüncü sıklıkta görülen kanserlerdir, rektum kanseri ise kolorektal kanserlerin %40'ını oluşturur (2).

Kolorektal kanserlerin insidansı 2001-2010 yılları arasında %3,4 azalmıştır (3). Rektum kanserinin tedavi sonrası takiplerinde başarı oranı son yıllarda önemli derecede gelişme göstermiştir. 5 yıllık sağ kalım oranı 1975 ve 1977 yılları arasında %48 iken; 2003 ve 2009 yılları arasında ise %68'e yükselmiştir (4). Bu gelişimin olmasında öncelikle rektum kanseri

tedavisinin köşe taşı olan cerrahi tekniklerin teknolojik gelişmeler doğrultusunda gelişmesi, tedavi sürecinin multidisipliner ekipler tarafından yönetilmesi; radyoloji, nükleer tıp, medikal onkoloji ve radyasyon onkolojisi alanında olan gelişmeler sayesinde olmuştur. Ayrıca kanser tarama testlerindeki farkındalık da erken tanı sağlayarak mortalite oranlarını azaltmaktadır.

Tanı

Rektum kanseri tanısı detaylı bir hasta öyküsü sonrası yapılan rektal muayene ile başlar ve kolonoskopik yöntemlerle alınan doku örneğinin histopatolojik inceleme sonrası değerlendirilmesiyle kesin tanı konulur. Tablo 1'de rektum kanserinde tanısal araçlar gösterilmiştir.

Tablo 1. Primer rektum kanserinde tanısal araçlar

| Parametre | Tanısal yöntem | |
|------------------------------------|--|-----------|
| Tümörün yeri (anal kanala uzaklık) | Rektal tuşe, sigmoidoskopi | |
| Patoloji | Biyopsi | |
| Klinik T evresi | erken | ERUS, MRI |
| | orta, ileri | MRI, ERUS |
| Sfinkter tutulumu | MRI, ERUS | |
| Klinik N evresi | MRI, CT, ERUS | |
| M evresi | Thoraks ve abdomen tomografisi, üst abdominal MRI, PET | |

¹ Op.Dr. Sami BENLİ, Mersin Üniversitesi Tıp Fakültesi, Cerrahi Onkoloji BD, benlisami@outlook.com

organları (erkeklerde prostat ve seminal veziküller, kadınlarda uterus, yumurtalıklar ve vajina) dahil olmak üzere tüm pelvik organların çıkarılması şeklindedir (75). Kısmi bir pelvik ekzentasyon, rezeke edilen organ veya yapılarla bağlı olarak anterior, posterior, supralelevator veya kompozit olabilir. Rektum kanseri için bir multiviseral rezeksiyon sıklıkla posterior veya supralelevator kısmi pelvik ekzentasyon gerektirir. Pelvik eksantasyon ilk olarak 1948'de tekrarlayan servikal karsinomun palyatif tedavisi için tanımlanmıştır (76).

Kaynaklar

1. R Glynne-Jones, L Wyrwicz, E Tiret, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Ann Oncol.* 2018;29(4):iv22-iv40. doi: 10.1093/annonc/mdy161.
2. Keskinilic, B., Gultekin, M., Akarca, A.S. (2016). *Turkey Cancer Control Program.* Republic of Turkey, Ministry of Health Turkey Public Health Institution Cancer Control Department. (1st Ed) Ankara.
3. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. 2014. *CA Cancer J Clin.* 2014;64:104–117.
4. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. *Cancer.* 2006;107(7):1624–1633.
5. Amin, MB., Greene, FL., Edge, S., et al. (2017). *AJCC Cancer Staging Manual* (8th Ed). New York: Springer.
6. Lindsetmo R-O, Joh Y-G, Delaney C-P. Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. *World J Gastroenterol.* 2008;14(21):3281–3289. doi: 10.3748/wjg.14.3281.
7. Wexner, SD., Jorge, JMN. (2005). Chapter 1. Anatomy and embryology of the anus, rectum, and colon. Corman ML (Ed) . In: *Colon & Rectal Surgery* (5th ed., p.1). Lippincott Williams & Wilkins, Philadelphia.
8. Diakosavvas M, Thomakos N, Psarris A, et al. Preoperative bowel preparation in minimally invasive and vaginal gynecologic surgery. *Sci World J.* 2020;8546037.
9. Vo E, Massarweh NN, Chai CY, et al. Association of the addition of oral antibiotics to mechanical bowel preparation for left colon and rectal cancer resections with reduction of surgical site infections. *JAMA Surg.* 2018;153(2):114–121.
10. Koller SE, Bauer KW, Egleston BL, et al. Comparative effectiveness and risks of bowel preparation before elective colorectal surgery. *Ann Surg.* 2018;267(4):734–742.
11. Morris MS, Graham LA, Chu DI, et al. Oral antibiotic bowel preparation significantly reduces surgical site infection rates and readmission rates in elective colorectal surgery. *Ann Surg.* 2015;261(6):1034–1040.
12. Contant CM, Hop WC, van't Sant HP, et al. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. *Lancet.* 2007;370:2112–2117.
13. Jung B, Pählman L, Nyström PO, et al. Mechanical Bowel Preparation Study Group. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. *Br J Surg.* 2007;94:689–695.
14. Bucher P, Gervaz P, Soravia C, et al. Randomized clinical trial of mechanical bowel preparation versus no preparation before elective left-sided colorectal surgery. *Br J Surg.* 2005;92:409–414.
15. Eskicioglu C, Forbes SS, Fenech DS, et al. Best Practice in General Surgery Committee. Preoperative bowel preparation for patients undergoing elective colorectal surgery: a clinical practice guideline endorsed by the Canadian Society of Colon and Rectal Surgeons. *Can J Surg.* 2010;53:385–395.
16. Jung B, Pählman L, Nyström PO, et al, Mechanical Bowel Preparation Study Group Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. *Br J Surg.* 2007;94:689–695.
17. Contant CM, Hop WC, van't Sant HP, et al. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. *Lancet.* 2007;370:2112–2117.
18. Pineda CE, Shelton AA, Hernandez-Boussard T, et al. Mechanical bowel preparation in intestinal surgery: a meta-analysis and review of the literature. *J Gastrointest Surg.* 2008;12:2037–2044.
19. Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev.* 2009;(1):CD001181.
20. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surg Infect (Larchmt).* 2013;14:73–156.
21. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? *Br J Surg.* 1982;69(10):613–616.
22. Heald RJ. The 'Holy Plane' of rectal surgery. *J R Soc Med.* 1988;81:503–580
23. Ross A, Rusnak C, Weirnerman B, et al. Recurrence and survival after surgical management of rectal cancer. *Am J Surg.* 1999;177:392–395.
24. Bjerkeset T, Edna TH. Rectal cancer: the influence of type of operation on local recurrence and survival. *Eur J Surg.* 1996;162(8):643–648.
25. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. *J Natl Cancer Inst.* 2001;93:583–596.
26. Wolmark N, Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma. A report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. *Ann Surg.* 1986;204:480–489.

27. Andreola S, Leo E, Belli F, et al. Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. *Dis Colon Rectum*. 1997;40:25-29.
28. Bujko K, Rutkowski A, Chang GJ, et al. Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review. *Ann Surg Oncol*. 2012;19:801-808.
29. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. *Lancet*. 2009;373:821-828.
30. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? *J Clin Oncol*. 2008;26:303-312.
31. Gosens MJ, Klaassen RA, Tan-Go I, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. *Clin Cancer Res*. 2007;13:6617-6623.
32. Nagtegaal ID, van de velde CJ, van der Worp E, et al. Macroscopic evaluation of rectal cancer resection specimens: clinical significance of the pathologist in quality control. *J Clin Oncol*. 2002;20:1729-1734.
33. Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectum excision for rectal cancer. *Br J Surg*. 2002;89:327-334.
34. Monson JR, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). *Dis Colon Rectum*. 2013;56:535-550.
35. Matsuda K, Hotta T, Takifuji K, et al. Randomized clinical trial of defaecatory function after anterior resection for rectal cancer with high versus low ligation of the inferior mesenteric artery. *Br J Surg*. 2015;102:501-508.
36. Mari GM, Crippa J, Coccoza E, et al. Low Ligation of Inferior Mesenteric Artery in Laparoscopic Anterior Resection for Rectal Cancer Reduces Genitourinary Dysfunction: Results From a Randomized Controlled Trial (HIGHLOW Trial). *Ann Surg*. 2019;269:1018-1024.
37. Komen N, Slieker J, de Kort P, et al. High tie versus low tie in rectal surgery: comparison of anastomotic perfusion. *Int J Colorectal Dis*. 2011;26:1075-1078.
38. Huerta, S., Dineen, SP. (2013). Current strategies in the management of adenocarcinoma of the rectum. In: Rangel L, editor. *Cancer treatment-conventional and innovative approaches*. Rijeka: Intech.
39. Rajput A, Romanus D, Weiser MR, et al. Meeting the 12 lymph node (LN) benchmark in colon cancer. *J Surg Oncol*. 2010;102:3-9.
40. National Comprehensive Cancer Network. *NCCN Guidelines for Rectal Cancer Version 1*; 2021. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
41. Miller ED, Robb BW, Cummings OW, et al. The effects of preoperative chemoradiotherapy on lymph node sampling in rectal cancer. *Dis Colon Rectum*. 2012;55:1002-1007.
42. Malakorn S, Yang Y, Bednarski BK, et al. Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation? *Dis Colon Rectum*. 2019;62(10):1158-1166.
43. Kusters M, Slater A, Muirhead R, et al. What to do with lateral nodal disease in low locally advanced rectal cancer? A call for further reflection and research. *Dis Colon Rectum*. 2017;60(6):577-585
44. Christou N, Meyer J, Toso C, et al. Lateral lymph node dissection for low rectal cancer: is it necessary? *World J Gastroenterol*. 2019;25(31):4294-4299.
45. Sugihara K, Moriya Y, Akasu T, et al. Pelvic autonomic nerve preservation for patients with rectal carcinoma: oncologic and functional outcome. *Cancer*. 1996;78:1871-1880.
46. Moriya Y, Hojo K, Sawada T, et al. Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer. *World J Surg*. 1997;21:728-732. doi:10.3393/jksc.2012.28.5.265
47. Watanabe, T., Ishihara, S. (2018). Management of Lateral Pelvic Lymph Nodes. In: Chang GJ, editor. *Rectal Cancer: Modern Approaches to Treatment*. Cham: Springer International Publishing; pp. 213-230.
48. Akiyoshi T, Watanabe T, Miyata S, et al. Japanese Society for Cancer of the Colon and Rectum. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: Is it regional or distant disease? *Ann Surg*. 2012;255:1129-1134.
49. van de Velde CJ, Boelens PG, Borras JM, et al. EURECA colorectal: Multidisciplinary management: European consensus conference colon amp; rectum. *Eur J Cancer*. 2014;50:1.e1-1.e34.
50. Ogawa S, Itabashi M, Inoue Y, et al. Lateral pelvic lymph nodes for rectal cancer: A review of diagnosis and management. *World J Gastrointest Oncol*. 2021;13(10):1412-1424. doi: 10.4251/wjgo.v13.i10.1412.
51. Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multi-center Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. *J Clin Oncol*. 2019; 37:33-43.
52. Ogura A, Konishi T, Beets GL, et al. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy. *JAMA Surg*. 2019;154:e192172.
53. Kawai K, Shiratori H, Hata K, et al. Optimal Size Criteria for Lateral Lymph Node Dissection After Neoadjuvant Chemoradiotherapy for Rectal Cancer. *Dis Colon Rectum*. 2021;64:274-283.
54. Malakorn S, Yang Y, Bednarski BK, et al. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation? *Dis Colon Rectum*. 2019; 62:1158-1166.

55. Ross A, Rusnak C, Weirman B, et al. Recurrence and survival after surgical management of rectal cancer. *Am J Surg*. 1999;177:392–395.
56. Quirke P, Durdey P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. *Lancet*. 1986;2:996–999.
57. Garcia-Granero E, Faiz O, Munoz E, et al. Macroscopic assessment of mesorectal excision in rectal cancer: a useful tool for improving quality control in a multidisciplinary team. *Cancer*. 2009;115:3400–3411.
58. McCourt M, Armitage J, Monson JR. Rectal cancer. *Surgeon*. 2009;7:162–169.
59. Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl_4):iv22–iv40.
60. Monson JR, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). *Dis Colon Rectum*. 2013;56:535–550.
61. Salinas HM, Dursun A, Klos CL, et al. Determining the need for radical surgery in patients with T1 rectal cancer. *Arch Surg*. 2011;146:540–543.
62. Chang AJ, Nahas CS, Araujo SE, et al. Early rectal cancer: local excision or radical surgery? *J Surg Educ*. 2008;65:67–72.
63. Buess G, Kipfmüller K, Hack D, et al. Technique of transanal endoscopic microsurgery. *Surg Endosc*. 1988;2(2):71–75.
64. Buess G, Mentges B, Manncke K, et al. Minimal invasive surgery in the local treatment of rectal cancer. *Int J Colorectal Dis*. 1991;6(2):77–81.
65. Arezzo A, Passera R, Saito Y, et al. Systematic review and meta-analysis of endoscopic submucosal dissection versus transanal endoscopic microsurgery for large noninvasive rectal lesions. *Surg Endosc*. 2014;28(2):427–438.
66. Chiniyah M, Ganganah O, Cheng Y, et al. Transanal endoscopic microsurgery is an oncologically safe alternative to total mesorectal excision for stage I rectal cancer: results of a meta-analysis of randomized controlled trials. *Int J Colorectal Dis*. 2016;31(8):1501–1504.
67. Lorenz C, Nimmegern T, Back M, et al. Transanal single port microsurgery (TSPM) as a modified technique of transanal endoscopic microsurgery (TEM). *Surg Innov*. 2010;17(2):160–163.
68. Chen YT, Kiu KT, Yen MH, et al. Comparison of the short-term outcomes in lower rectal cancer using three different surgical techniques: Transanal total mesorectal excision (TME), laparoscopic TME, and open TME. *Asian J Surg*. 2019;42(6):674–680. doi: 10.1016/j.asjsur.2018.09.008.
69. Miles WE. A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon (1908). *CA Cancer J Clin*. 1971;21(6):364–4.
70. Murrell ZA, Dixon MR, Vargas H, et al. Contemporary indications for and early outcomes of abdominoperineal resection. *Am Surg*. 2005;71:837–840.
71. den Dulk M, Putter H, Collette, et al. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. *Eur J Cancer*. 2009;45(7):1175–1183.
72. Holm T, Ljung A, Häggmark T, et al. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. *Br J Surg*. 2007;94(2):232–238.
73. West NP, Anderin C, Smith KJ, et al. Multicentre experience with extralevator abdominoperineal excision for low rectal cancer. *Br J Surg*. 2010;97(4):588–599.
74. Rullier E, Denost Q, Vendrely V, et al. Low rectal cancer: classification and standardization of surgery. *Dis Colon Rectum*. 2013;56:560–567.
75. Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. *J Am Coll Surg*. 2000;190:78–83.
76. Harris CA, Solomon MJ, Heriot AG, et al. The Outcomes and Patterns of Treatment Failure After Surgery for Locally Recurrent Rectal Cancer. *Ann Surg*. 2016;264(2):323–329.